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Objective: This study examines the incidence and factors associated with the failure
of homograft valves and identifies those factors that are modifiable.
Methods: From 1990 to 2001, 96 homograft valves were implanted in the right
ventricular outflow tract of 83 children (mean age 5.1 5.6 years). Clinical and blinded
serial echocardiographic follow-up was performed on all 90 valves in the 77 survivors.
Results: Eighteen homograft valves were replaced as the result of pulmonary
insufficiency (3), stenosis (9), or both (6). Freedom from reoperation was 71% at 9
years (95% confidence interval, 58%-84%). Forty-eight valves developed progres-
sive pulmonary insufficiency of at least 2 grades, 26 valves developed transvalvular
gradients of 50 mm Hg or greater, and 14 of these valves were also insufficient. The
freedom from echocardiographic failure (progressive pulmonary insufficiency 2
grades or 50 mm Hg gradient) was only 27% at 5 years (95% confidence interval,
17%-37%). In a multivariate analysis (Cox regression), use of an aortic homograft
(P  .001) and short antibiotic preservation time (P  .04) were associated with
reoperation. Younger age (P  .01), ABO mismatch (P  .04), and diagnosis (P 
.005) were associated with echocardiographic failure. In the subanalysis of patients
with human leukocyte antigen typing, age (P  .002), aortic homograft (P  .04),
and human leukocyte antigen-DR mismatch (P  .03) were associated with echo-
cardiographic valve failure.
Conclusion: Many homografts rapidly become insufficient and require replacement.
In our analysis of both reoperation and echocardiographic failure, several immuno-
logic factors are consistently associated with homograft failure. Matching for human
leukocyte antigen-DR, blood group, and avoiding short preservation times (thus
minimizing antigenicity) offers the potential to extend the life of these valves.
Homografts in the aortic position have good longevity in adults,similar to that achieved with bioprosthetic valves.1,2 In the pul-monary position, the homograft is also a reasonably reliablevalve.3,4 However, homografts are prone to early failure in chil-dren.5,6 There is mounting evidence that the valves incite animmunologic response, and that this may be associated with their
failure.7-11 However, homograft valves remain the best option for valve replacement in
young children.
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There is evidence that factors in homograft procurement
and preservation, as well as homograft type and blood type,
are associated with preserved immunogenicity and may be
associated with valve failure.6,9,10 In vitro evidence indi-
cates that human leukocyte antigen (HLA)-DR and ABO
matching, as well as changes in preservation, can alter the
immune response to cryopreserved homografts.12,13 HLA
class I and II antibodies are known to be elevated in children
receiving homografts,14 and it seems that HLA class II is
particularly important.7,15 Despite this, it is not clear
whether these factors are directly related to homograft valve
failure in clinical practice.8,9,16,17
This study examines the factors associated with ho-
mograft failure in children and identifies those factors that
may be modifiable.
Methods
Patient Population
Between December 1990 and May 2001 at the Izaak Walton
Killam Grace Hospital, 96 consecutive cryopreserved homograft
valves were implanted for right ventricular outflow tract recon-
struction in 83 patients (39 female, 44 male) with a variety of
congenital lesions (Table 1). The mean age at operation was 61
months  67 months, (median 36 months, range 1 day–19 years).
Fifty-four of the 83 patients (65%) had undergone at least 1
previous operation. Some of the results of the first 44 of these
patients have been reported.6
Homograft Procurement and Preparation
All valves were harvested en bloc under sterile conditions by a
surgeon or tissue-bank technologist. The valves were incubated in
500 mL of Hank’s balanced salt solution containing 40 mg of
gentamicin and 500 mg of cefazolin at 4°C for 12 to 72 hours. The
valves were cryopreserved in Hank’s solution with 10% dimeth-
ylsulfoxide as a cryoprotectant. They were cooled in a controlled-
rate freezer (Planer KRY010, Planer Products Ltd., Sunbury-on-
Thames, Middlesex, UK) at 1°C per minute to a temperature of
80°C and stored in vapor phase liquid nitrogen less than135°C
until used. The homografts were transported in a cooler of liquid
nitrogen to the operating theater and thawed in a water bath for 10
minutes before use. Procurement and preservation times according
to the protocols were as follows: warm ischemic time less than 24
hours, cold ischemic time less than 24 hours, antibiotic storage
time 24  2 hours (since 1996), and cold ischemic time and
antibiotic time 30 hours or more. These times were the same
throughout the study except for the antibiotic preservation time
(retrieval to preservation time), which was increased to a minimum
of 24 hours in 1996 on the basis of our previous findings.6
All homograft data were prospectively collected. Details of
preservation and ischemic times were collected on all the valves.
Ninety-six valves were harvested from 80 donors. Three valves
were purchased elsewhere (2 of which lacked preservation data).
HLA status was available for 52 of the 96 valves (Table 2).
Tissue Typing
Tissue typing was performed by the National Institutes of Health
technique. Briefly, T lymphocytes were incubated at room tem-
perature for 30 minutes with anti-HLA sera in a 72-well microtray
(Biotest AG, Dreieich, Germany). Rabbit complement (Biotest
AG) was added, and the tray was incubated for a further 60
minutes at room temperature. Eosin (vital stain) and formaldehyde
(fixative) were added, and the reactions visualized with an inverted
phase microscope.
For HLA-DR, DNA was extracted by means of a salting-out
technique and added to a commercial sequence-specific primer
typing tray (GenoVision AS, Oslo, Norway) along with the ap-
propriate thermostable enzyme and buffer. After 10 cycles (94°C
for 10 seconds, 65°C for 60 seconds) on a PE 9700 thermocycler
(Perkin Elmer, Norwalk, Conn), the reaction products were visu-
alized by ethidium bromide staining on an agarose gel.
From 1990 to 1995, tissue typing was available for 15 of the 48
valves. Since 1996, donors and recipients of all homografts har-
vested have been routinely tissue typed. Tissue typing was avail-
able for 52 of the valves and 47 of the recipients. HLA-DR match
was defined as both loci matched (2/2) or a homozygous donor
matching 1 of the recipient alleles.
Operative Technique
All valves were implanted by 1 of 2 surgeons. The operations were
performed through a median sternotomy with standard cardiopul-
monary bypass techniques and mild hypothermia (32°C). The
aortic root was not routinely cross-clamped unless other proce-
dures, such as ventricular septal defect closure or an autograft,
were required. In 12 patients, the reconstruction involved implant-
TABLE 1. Patients with homograft valves
Primary diagnosis No.
Pulmonary atresia/ventricular septal defect 25
Tetralogy of Fallot/double-outlet right ventricle 18
Complex transposition 17
Aortic stenosis (Ross procedure) 12
Truncus arteriosus 11
Total 83
TABLE 2. Homograft valve characteristics
Mean  SD Median Range
Sex (50 male, 30 female
patients)
Tissue only donor 51
Multiorgan donor 23
Heart transplant recipient 6
Age 16.6 15.3 yr 13 yr (3 d–60 yr)
*Valve size 17.3 4.4 mm 18 mm (9-29 mm)
†Warm ischemic time 4.4 4.6 hr 2.5 hr (0-18.5 hr)
‡Cold ischemic time 2.7 4.9 hr 1 hr (1-37 hr)
§Antibiotic preservation time 32.4 10.5 hr 30.3 hr (12-72 hr)
*Internal diameter at the annulus.
†Time from heart cessation to end of harvest.
‡Time from end of harvest to start of antibiotic preservation.
§Time of treatment in antibiotics and Hank’s solution at 4°C.
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ing the homograft as a bifurcated graft. Proximal extensions of
autologous pericardium or homograft material were added in 38
patients. Four patients had proximal Dacron (Dupont, Wilmington,
Del) polyester fiber extensions. Valve size was determined intra-
operatively. We always attempted to insert the largest possible
valve. In all cases, the valve was larger than the minimally accept-
able pulmonary annulus diameter, as previously published.18 Pul-
monary valves were used preferentially throughout the period;
since 1996, attempts have been made to match for blood type.
Follow-up
All patients were followed by the cardiology clinic; no patients
were lost to follow-up. Patients were seen routinely at 1 to 2
months postoperatively and then every 3 to 6 months or yearly, as
dictated by the clinical condition. The guidelines for reporting
morbidity and mortality after cardiac valvular operations were
followed for the reporting of outcomes.19
Echocardiographic Evaluation
All patients underwent at least 1 transthoracic echocardiographic
study in the immediate postoperative period. They were then
reexamined serially every 6 to 12 months. All the studies were
performed in a standardized fashion by 1 of 2 echocardiographic
nurses. All studies were retrospectively reviewed in a random and
blinded fashion by a single pediatric cardiologist; 10% of these
were re-reviewed randomly by the same cardiologist without his
knowledge. In addition, a second pediatric cardiologist, also in a
random and blinded fashion, reviewed 10% of the studies. The
interobserver and intraobserver variability in scoring was assessed
using the kappa coefficient.20
Echocardiographic observations were made with short-axis
parasternal views. Stenosis was assessed by measuring the peak
velocity through the valve with continuous-wave Doppler tech-
nique. All studies were assessed for valve insufficiency using a
graded semiquantitative score. The severity was graded as 0 (ab-
sent), 1 (a pinhole jet), 2 (a jet of regurgitation approximately
20% of the valve annulus), 3 (a wide-based jet approximately
40% of the annular width), and 4 (a broad jet 40% of the
annular width).3,6,21,22
Statistical Analysis
Data are presented as mean  standard deviation, median, and
range. All statistical tests were performed with SAS version 8.1
(SAS Institute, Inc., Cary, NC). Bivariate analysis was performed
using 2-sided t tests or the chi-square test and Fischer exact tests.
Actuarial estimates of freedom from postoperative events were
performed with Kaplan-Meier methods.23 Cox proportional haz-
ards regression was used for multivariate analysis. Cox propor-
tional hazards analysis model diagnostics and likelihood ratio tests
for goodness of fit were performed. Hazard ratios and 95% con-
fidence intervals (CIs) were estimated from these models.24
Figure 1. Kaplan-Meier curve of freedom from reoperation for homograft valve failure for the 90 operative survivors.
The number of patients at risk is given above the horizontal axis. Freedom from reoperation is expressed as a
percentage with 95% confidence intervals (CIs).
TABLE 3. Risk factors for reoperation for homograft failure
Covariates Bivariate
Multivariate
hazard ratio
(95% CI)
Valve type (pulmonary vs aortic) P  .006 0.10 (0.04-0.40)
Antibiotic preservation time P  .03 0.90 (0.80-0.95)
Patient age P  .008 NS
Donor age P  .004 NS
Weight P  .002 NS
Valve size P  .001 NS
Peripheral pulmonary stenosis P  .05 NS
CI, Confidence interval; NS, not significant.
Baskett et al Surgery for Congenital Heart Disease
234 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
CH
D
The outcomes analyzed were death, reoperation for valve fail-
ure, and echocardiographic valve failure. Reoperation was under-
taken for pulmonary insufficiency associated with right ventricular
dysfunction and dilatation or gradients exceeding 70 to 80 mm Hg.
Echocardiographic valve failure was defined as a progression of 2
or more grades of insufficiency or a peak transvalvular gradient 50
mm Hg or more.
Potential variables evaluated in the multivariable analysis in-
cluded the following: The patient factors were age, sex, weight,
diagnosis, peripheral pulmonary stenosis, and redo homograft. The
homograft factors were valve type (aortic/pulmonic), valve size,
donor age, donor sex, warm ischemic time, cold ischemic time,
antibiotic preservation time, blood group mismatch, and HLA-DR
mismatch (2/2 no mismatch, 0/2 and 1/2mismatch) (Table 2).
Results
There were 6 early postoperative deaths, 5 in neonates with
truncus arteriosus and 1 in a patient with pulmonary atresia.
One late death as the result of pulmonary embolus occurred
2 months after a second homograft replacement in a patient
with double outlet right ventricle. No patients were lost to
follow-up. Patients were followed for a mean of 55  35
months (median 56 months, range 2-142 months). Actuarial
survival was 92% at 10 years (95%, CI 89%-95%).
Reoperation
Eighteen valves were replaced as the result of pulmonary
insufficiency (n  3) or stenosis (n  9) or both (n  6).
Freedom from reoperation for homograft valve failure was
71% at 7 years (95% CI 64%-77%) (Figure 1). The mean
time to reoperation was 42.6  33.6 months (median 39.5,
range 5–127 months). There were no deaths at reoperation;
15 patients underwent replacement with a second or third
homograft, and 3 patients had a bioprosthetic valve inserted.
In the bivariate analysis, several factors were found to be
associated with reoperation (Table 3). In the forward step-
wise Cox regression analysis, only 2 variables, homograft
type (aortic) and shorter time of antibiotic preservation,
were associated with the need for reoperation for valve
failure.
Echocardiographic Results
Postoperative echocardiograms were obtained for all survi-
vors at a mean of 8.2 9.2 days (median 7 days, range 1-41
days). At this first echocardiographic evaluation, no patients
had greater than 1 insufficiency or gradients greater than
15 mm Hg. A total of 523 studies were reviewed by the
primary cardiologist, 10% of which were re-reviewed at
random by the same observer and 10% by the second
cardiologist.
The kappa coefficients for interobserver agreement for
the assessment of pulmonary insufficiency were 0.73 and
0.70 for peak gradient, both indicating substantial agree-
ment.20 The intraobserver agreement was better with coef-
ficients of 0.80 and 0.78, respectively.
Echocardiographic Valve Failure
Sixty of 90 valves failed by our echocardiographic criteria;
48 valves developed progressive insufficiency of 2 or more
grades, and 26 homografts developed transvalvular gradi-
ents 50 mm Hg or greater (14 of these valves also had 2
grades of insufficiency). The freedom from echocardio-
graphic valve failure (progression of 2 grades of insuffi-
ciency or 50 mm Hg gradient or both) was 27% at 5 years
(95% CI, 17%-37%) (Figure 2). The mean time to echocar-
diographic failure was 11.2 13.5 months (median 6, range
Figure 2. Kaplan-Meier curve of freedom from echocardiographic failure for the 90 operative survivors (echocar-
diographic valve failure was defined as a progression of >2 grades of insufficiency or a peak transvalvular
gradient >50 mm Hg). The number of patients at risk is given above the horizontal axis. Freedom from
echocardiographic failure is expressed as a percentage with 95% CIs.
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3-65). Patients who developed valve failure had a nonstatis-
tically significant shorter follow-up, with a mean of 50 30
months (median 49 months, range 3-113 months), than
those who did not develop homograft failure, with a mean of
67 42 months (median 71, range 2-142 months; P .07).
Comparison of valve failure from insufficiency and ste-
nosis shows that insufficiency was more common and de-
veloped much more rapidly than from stenosis (Figure 3).
The freedom from progression of homograft insufficiency
of 2 or more grades was 40% at 4 years (95% CI, 34%-
46%), and the freedom from stenosis of 50 mm Hg or
greater was 58% at 4 years (95% CI, 51%-65%; log-rank
test P  .001). The mean time to failure from insufficiency
was 8.5  10.1 months (median 6 months, range 2-50
months). In contrast, the mean time to failure from stenosis
was 19.7  18.6 months (median 13 months, range 2-65
months; P  .03).
In the bivariate analysis, several factors were associ-
ated with failure. In the multivariate analysis of echocar-
diographic homograft valve failure, only younger age at
operation, blood group mismatch, and the diagnosis of
pulmonary atresia were associated with valve failure
(Table 4).
Figure 3. Kaplan-Meier curve of freedom from echocardiographic failure for the 90 operative survivors. A, A
progression of 2 or more grades of insufficiency. B, A peak transvalvular gradient 50 mm Hg or greater. The number
of patients at risk is given above the horizontal axis. Freedom from echocardiographic failure is expressed as a
percentage with 95% CIs (log-rank test P  .01).
TABLE 4. Risk factors for homograft valve failure
Covariates Bivariate
Multivariate
hazard ratio
(95% CI)
Patient age P .0001 0.98 (0.96-0.99)
ABO match P .01 0.51 (0.27-0.96)
Diagnosis (pulmonary atresia) P .27 2.53 (1.1-12.2)
Donor age P .001 NS
Weight P .001 NS
Valve size P .001 NS
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In separate bivariate analyses of failure caused by insuf-
ficiency or stenosis alone, blood group mismatch, age,
weight, and valve size were significantly associated with
failure caused by insufficiency, whereas only valve type
(aortic) was significantly associated with failure caused by
stenosis. In the multivariate analysis of failure caused by
insufficiency, there was a nonsignificant trend toward age,
valve type, and ABO mismatch being associated with fail-
ure.
HLA Analysis
A subanalysis was conducted of valves for which tissue
typing was available for both the donor and the recipient (n
 47), with echocardiographic valve failure as the outcome.
Eighteen of 27 HLA-DR mismatched patients developed
echocardiographic valve failure compared with 8 of 20
matched patients (P  .07). The 5-year freedom from
echocardiographic homograft valve failure for matched and
unmatched patients was 49% versus 33% (log-rank test P
.67). In the bivariate analysis, only blood group mismatch
was significantly associated with echocardiographic failure.
However, in the multivariate analysis, younger age, valve
type (aortic), and complete HLA-DR mismatch were asso-
ciated with valve failure (Table 5).
Discussion
We demonstrated for the first time that homograft valve
failure in children is associated with HLA-DR mismatch.
Furthermore, there is a consistent association between var-
ious factors in homograft procurement and preservation that
is known to preserve immunogenicity and homograft fail-
ure. Specifically, blood group mismatch, short antibiotic
preservation time, and valve type (aortic) are all associated
with homograft valve failure.
In Dignan and colleagues’9 study of aortic homografts in
adults, there was a bivariate association between HLA-DR
mismatch and homograft deterioration in patients followed
for more than 5 years. This association did not remain in the
multivariate analysis. Their finding of an association be-
tween a short time from retrieval to cryopreservation and
homograft structural deterioration (defined as a peak gradi-
ent 50 mm Hg or 3 and 4 insufficiency) confirms our
earlier findings in children,6 which are also confirmed in the
present study. Smith and colleagues’16 series of adult non-
cryopreserved homografts found a nonsignificant trend to-
ward increased valve dysfunction in patients who developed
HLA antibodies, but no association between HLA mismatch
and valve failure or reoperation. The failure to show a
significant effect of HLA matching in adults is likely a
reflection of the weaker immune response to homografts
seen in adults, the duration of follow-up, and the lower
incidence of valve failure in the adult patient.
It is clear that children and adults respond differently to
homografts. Virtually all studies have found younger age to
be a predictor of early failure.3,5,6,9 A donor-specific anti-
body response is induced by homograft implantation.7,10,15
There is evidence that children produce a virulent T-cell
response, whereas adults mount a much weaker response.8
In addition, laboratory studies have demonstrated that allo-
graft valve destruction is T-cell mediated.25
This current study is limited by the small number of
patients, particularly the subanalysis of the HLA-typed pa-
tients. However, this is one of the largest series with such
detailed follow-up. There is consistency of the results
among the different analyses, and the variables identified
are consistent with the results of other studies.3,8,9 It is likely
that the other HLA loci and nonimmunologic factors, in-
cluding growth, degeneration, and technique, play a role in
homograft failure.14 However, the timing of the failure is
more consistent with rejection.
An important advantage of our serial echocardiographic
follow-up (every 6-12 months) is that the time to failure can
be accurately identified. An observation arising from this is
that the failure, particularly resulting from insufficiency,
occurs quite early (Figure 3).
There are promising new technologies attempting to re-
duce or eliminate the antigenicity of homografts.26-28 At
present, homografts seem to still be the best option for right
ventricular outflow tract reconstruction in children.29,30
Some clinical efforts have been made for the use of immu-
nosuppression, but there is no evidence that this works.
Laboratory studies indicate that long-term rather than short-
term immunosuppression would be required.25 Despite this,
some groups advocate routine immunosuppression in
younger patients.31
The present state of knowledge does not seem to warrant
routine immunosuppression. However, there is good evi-
dence that ensuring valves are matched for HLA-DR and
blood group, and that storage and procurement times are
optimized, may delay valve failure with little or no risk to
the recipient.
In summary, we have found that several important fac-
tors in homograft preservation and selection are associated
TABLE 5. Risk factors for homograft valve failure (subset
with tissue typing, n  47)
Covariates Bivariate
Multivariate
hazard ratio
(95% CI)
HLA-DR match P  .07 0.10 (0.01-0.94)
Age (mo) P  .16 0.88 (0.82-0.95)
Valve type (pulmonary vs
aortic)
P  .08 0.20 (0.02-0.89)
ABO match P  .03 NS
HLA, Human Leukocyte antigen; HR, hazard ratio.
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with failure of the valves. Several of these, including valve
type, preservation times, blood type, and HLA-DR mis-
match, are modifiable and thus can be used to improve
clinical results.
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Discussion
Dr David R. Clarke (Denver, Colo). Congratulations to Dr
Baskett and his coauthors are certainly in order for an excellent
clinical study and presentation.
This study clearly puts yet another nail in the coffin of the
theory that cryopreserved allografts do not elicit an immune re-
sponse. It also goes further and irrefutably links ABO and HLA
incompatibility to graft failure determined by the need for reop-
eration or echocardiographic evidence of progressive regurgitation
or significant stenosis. Two other risk factors identified could also
be associated with an immune phenomenon: Use of an aortic
homograft and shorter warm ischemic time could presumably lead
to the implantation of a higher antigenic load. Are there other
possible explanations for the appearance of these risk factors?
Dr Baskett. It is a hard group of patients to look at, as I know
you are well aware. There is so much we do not know about how
the preservation affects the valves. I think some of the clinical
factors, such as the diagnosis of pulmonary atresia, which often
goes along with peripheral pulmonary stenosis, probably unmask
failure sooner than you may see in a patient, for example, with a
Ross procedure (in which there is not the same need for a com-
petent valve). But as you point out, there seems to be a consistent
association among several factors that are known to increase the
antigenic load and valve failure. This seems to keep coming
through in everybody’s work.
Dr Clarke. You also have identified age at operation as a risk
factor that has been identified in previous studies. In previous
studies, it seems that stenosis in younger patients was very com-
mon. Did you find a difference in the failure mode related to the
age of the patient at implantation?
Dr Baskett. That is a very good question. We did not look
specifically at that when we were constructing our statistical mod-
els. The different variables presented and how one chooses to
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